Up date in the management of advanced ovarian carcinoma-Reference-Cited by-同舟云学术

Up date in the management of advanced ovarian carcinoma

Published:1999-09 Issue:1 Volume:32 Page:49-58
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Conte P.F,Cianci C,Gadducci A

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference111 articles.

1. Surgery in the treatment of patients with advanced ovarian cancer;Hoskins;Semin Oncol,1991

2. Surgical staging and cytoreductive surgery of epithelial ovarian cancer;Hoskins;Cancer,1993

3. Randomized trial comparing two combination chemotherapy regimens (HEXA-CAF vs CHAP-5) in advanced ovarian cancer;Neijt;Lancet,1984

4. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas;Edmonson;Cancer Treat Rep,1985

5. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin,doxorubicin and cyclophosphamide in advanced ovarian cancer;Conte;J Clin Oncol,1986

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma;Journal of Gynecologic Oncology;2021

2. Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation;Oncology Reports;2018-04-18

3. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study;International Journal of Gynecologic Cancer;2016-01-01

4. Introduction;Atlas of Clear Cell Carcinoma of the Ovary;2015

5. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro;CHINESE J CANCER RES;2014